MedTrace Logo

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

NCT06885424 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-05-20

No results posted yet for this study

Summary

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Conditions

  • Solid Tumor Cancer
  • Solid Tumor, Unspecified, Adult
  • Colorectal Carcinoma
  • Colorectal Carcinoma (CRC)
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer ( SCLC )
  • Pancreatic Cancer
  • NSCLC
  • Mesothelioma
  • Ovarian Cancer
  • Ovarian Carcinoma
  • Head and Neck (HNSCC)
  • Head and Neck Cancer
  • Renal Cell Carcinoma (Kidney Cancer)
  • Triple Negative Breast Cancer (TNBC)

Interventions

OTHER

No additional intervention administered in this long term follow-up study

Safety follow-up for A2 Bio GT products administered in a previous interventional study

Sponsors & Collaborators

  • A2 Biotherapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Ng, MD · A2 Biotherapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2030-03-31
Completion
2040-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06885424 on ClinicalTrials.gov